(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Celcuity's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CELC's revenue for 2025 to be $218,610,595, with the lowest CELC revenue forecast at $218,610,595, and the highest CELC revenue forecast at $218,610,595. On average, 3 Wall Street analysts forecast CELC's revenue for 2026 to be $1,571,372,957, with the lowest CELC revenue forecast at $760,452,570, and the highest CELC revenue forecast at $2,373,486,460.
In 2027, CELC is forecast to generate $7,499,592,612 in revenue, with the lowest revenue forecast at $6,323,155,310 and the highest revenue forecast at $9,086,393,231.